Regeneron Pharmaceuticals, Inc [REGN] stock prices are up 0.45% to $733.59 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The REGN shares have gain 2.98% over the last week, with a monthly amount drifted -5.71%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Wolfe Research started tracking the stock with Outperform rating on November 15, 2024, and set its price target to $1150. On November 14, 2024, Citigroup initiated with a Neutral rating and assigned a price target of $895 on the stock. Leerink Partners downgraded its rating to a Market Perform and decreased its price target to $1077 on September 24, 2024. Bernstein initiated its recommendation with a Outperform and recommended $1125 as its price target on March 12, 2024. RBC Capital Mkts upgraded its rating to Outperform for this stock on January 12, 2024, and upped its price target to $1076. In a note dated November 09, 2023, Deutsche Bank initiated an Hold rating and provided a target price of $800 on this stock.
The stock price of Regeneron Pharmaceuticals, Inc [REGN] has been fluctuating between $693.00 and $1211.20 over the past year. Currently, Wall Street analysts expect the stock to reach $1132.71 within the next 12 months. Regeneron Pharmaceuticals, Inc [NASDAQ: REGN] shares were valued at $733.59 at the most recent close of the market. An investor can expect a potential return of 54.41% based on the average REGN price forecast.
Analyzing the REGN fundamentals
The Regeneron Pharmaceuticals, Inc [NASDAQ:REGN] reported sales of 13.85B for trailing twelve months, representing a surge of 10.65%. Gross Profit Margin for this corporation currently stands at 0.84% with Operating Profit Margin at 0.29%, Pretax Profit Margin comes in at 0.36%, and Net Profit Margin reading is 0.34%. To continue investigating profitability, this company’s Return on Assets is posted at 0.12, Equity is 0.17 and Total Capital is 0.12. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 725.03 points at the first support level, and at 716.48 for the second support level. However, for the 1st resistance point, the stock is sitting at 742.71, and for the 2nd resistance point, it is at 751.84.
Ratios To Look Out For
It’s worth pointing out that Regeneron Pharmaceuticals, Inc [NASDAQ:REGN]’s Current Ratio is 5.28. Further, the Quick Ratio stands at 4.46, while the Cash Ratio is 0.55. Considering the valuation of this stock, the price to sales ratio is 5.82, the price to book ratio is 2.75 and price to earnings (TTM) ratio is 18.15.
Transactions by insiders
Recent insider trading involved McCourt Marion, EVP Commercial, that happened on Nov 01 ’24 when 1000.0 shares were sold. Officer, MARION E MCCOURT completed a deal on Nov 01 ’24 to buy 1000.0 shares. Meanwhile, Director RYAN ARTHUR F sold 100.0 shares on Oct 01 ’24.
